Dear Editor,
Tuberculosis (TB), an infectious disease caused by the bacillus Mycobacterium tuberculosis, leads to substantial mortality worldwide [1] . The emergence of multidrugresistant (MDR) and extensively drug-resistant (XDR) strains of M. tuberculosis has challenged conventional anti-TB therapy and threatens global disease control of TB [2, 3] . The development of new anti-TB drugs is urgently required [4] . β-lactams are effective antibiotics widely used to treat bacterial infections; however, so far no effective anti-TB antibiotics have emerged from this class of drugs. Previous studies have indicated that an important reason for the lack of effective β-lactam anti-TB antibiotics is the presence of a chromosomallyencoded class A (Ambler) β-lactamase, BlaC, in M. tuberculosis [5] .
A recent study by Hugonnet et al. [6] has demonstrated that a combination of meropenem-clavulanate was effective against 13 XDR strains of M. tuberculosis. Meropenem is a member of the carbapenem class of β-lactams and contains a bicyclic nucleus, a pyrroline ring and a β-lactam ring, and clavulanate is a β-lactamase inhibitor. Both are FDA-approved drugs and could potentially be used to treat TB, providing a novel clinical treatment strategy [6] . However, the bactericidal mechanism of this drug combination in treating TB is unclear. Hugonnet et al. [6] suggest that one reason for the efficacy of the meropenem-clavulanate combination against XDR strains is that meropenem is poorly hydrolyzed by BlaC.
Carbapenems have been reported to target L,D-transpeptidases that generate the unusual 3→3 transpeptide linkages that are the predominant transpeptide linkages (80%) in the peptidoglycan layer of nonreplicating M. tuberculosis [7, 8] . L,D-transpeptidase type 2 (Ldt Mt2 ) is the main L,D-transpeptidase in M. tuberculosis and is critical for cell wall synthesis, virulence and amoxicillin tolerance of M. tuberculosis [9] . To kill M. tuberculosis effectively, the combination of meropenem-clavulanate not only inactivates β-lactamase but also prevents the formation of transpeptide linkages in the peptidoglycan layer [9] . As Ldt Mt2 is the enzyme that generates 80% of the transpeptide linkages in M. tuberculosis, the inactivation of Ldt Mt2 is likely to be the major mechanism underlying the effectiveness of meropenem-clavulanate against M. tuberculosis. Here, we report the crystal structures of an N-terminal-truncated Ldt Mt2 (Ldt Mt2 -∆N54, residues 55-408), a trypsin-degraded fragment of Ldt Mt2 (Ldt Mt2 -∆N139, residues 140-408) and the complex of Ldt Mt2 -∆N139 and meropenem, at 2.5, 1.8 and 1.4 Å resolutions, respectively (Supplementary information, Figure  S1 and Table S1 ). These structures reveal the structural mechanism through which meropenem may act to inhibit Ldt Mt2 .
Our apo Ldt Mt2 -∆N54 structure ( Figure 1A ) shows the linear arrangement of the two N-terminal β-barrel domains (residues 60-148 and 149-250) and the C-terminal YkuD domain (residues 251-408). The two N-terminal β-barrel domains, both of which adopt an IgG-like fold, contain one three-stranded and one four-stranded sheet, respectively. We suggest that these two IgG-like domains act as a spacer arm for the YkuD catalytic domain. The YkuD domain is characterized by a β-sheet structure similar to that in Ldt Bs from Bacillus subtilis [10] and Ldt fm from Enterococcus faecium [11] (Supplementary information, Figure S1 ) with a root-mean-square deviation of Cα superposition of 1.6 Å and 1.8 Å and sequence identities of 20% and 24%, respectively. As in Ldt Bs and Ldt fm [10, 11] , the YkuD domain in Ldt Mt2 contains a catalytic triad Cys354-His336-Ser337, and it is likely that residue Cys354 is directly involved in enzyme activity and is the target site for carbapenems. Ldt Mt2 also contains two additional segments, A (residues 300-323) and B (residues 379-408), which are not observed in Ldt Bs and Ldt fm (Supplementary information, Figure S1 ).
Co-crystallization of Ldt Mt2 -∆N54 and meropenem failed, but co-crystallization of Ldt Mt2 -∆N139 and me- the catalytic residue Cys354 via thioester formation. The carbapenem nucleus of meropenem appears clearly, displays well-defined electron densities and shows the same conformation in both State I and II ( Figure 1B and  1D) . The planar arrangement of atoms C2, C3, N4, C5, and C31 of meropenem in complex with Ldt Mt2 results in the appearance of a double bond between C3 and N4 ( Figure 1F ), replacing the C2/C3 double bond observed in meropenem [12, 13] . The C3/N4 double bond was also observed in meropenem covalently linked to BlaC [6] and other β-lactamases [13] . This tautomerism of the carbapenem nucleus is accompanied by the covalent linking of meropenem to Ldt Mt2 . As tautomerization of the carbapenem nucleus has been reported to cause slow turnover in carbapenem hydrolyzation by BlaC [6] and other β-lactamases [13] , we propose that tautomerization helps to stablize the Ldt Mt2 -meropenem adduct. Despite these similarities, the two states are distinct from each other. In State I, atom C7 of meropenem ( Figure  1F and Supplementary information, Figure S2 ) is close to atom N4 at a distance of 2.87 Å. This conformation is very similar to that reported previously for meropenem in complex with BlaC [6] , and likely represents the initial step during the action of meropenem on Ldt Mt2 . In State II, the carbapenem nucleus has flipped approximately 180 degrees around the single bond connecting atoms C5 and C6 (Supplementary information, Figure S3 ), resulting in a larger C7-N4 distance of 3.21 Å.
Interestingly, by flipping the carbapenem nucleus in State II, residue Tyr308 of Ldt Mt2 adopts a different rotamer conformation by rotating approximately 90 degrees around the Cα/Cβ bond (Supplementary information, Figure S3 ). We suggest that rotating of the Tyr308 side chain in Ldt Mt2 and flipping of the carbapenem nucleus in meropenem are the second step following the β-lactam ring opening in the first step during the action of meropenem on Ldt Mt2 , and result in three additional hydrogen bonds ( Tyr318 OHMer OH62, Tyr318 OHMer O32, and Tyr308 OHMer O32) between the enzyme and meropenem in State II ( Figure 1E and Supplementary information, Figure S3 ). In contrast, only one hydrogen bond ( Gly353 NMer O7) is observed in State I ( Figure 1D ). Residues Tyr308 and Tyr318 that form hydrogen bonds with meropenem are conserved in Ldt Mt2 and its homologs, but not in other L,D-transpeptidases (Supplementary information, Figure S1 ). Mutant protein Y318F or Y318A hydrolyzes meropenem at a faster rate than the wild-type protein (Supplementary information, Figure S4 ), supporting that the additional hydrogen bonds are important for stabilization of the enzyme-drug adduct and indicating that the flipping of meropenem and the resulting additional hydrogen bonds are involved in the mechanism underlying the inhibition of Ldt Mt2 by meropenem ( Figure 1F) .
As a main peptidoglycan-crosslinking L,D-transpeptidase, Ldt Mt2 is an important target in the development of drugs against XDR M. tuberculosis [9, 14] . Our analyses of the Ldt Mt2 -meropenem complex structure reveal a twostep mechanism of drug actions (Figure 1F top) . The first step involves opening the β-lactam ring of meropenem and formation of a thioester between meropenem and Ldt Mt2 , accompanied by the simultaneous tautomerization of the C2/C3 double bond to C3/N4 double bond (State I). These events of the first step are also observed in the complex of meropenem and BlaC [6] (Figure 1F  bottom) . During the second step, the C5/C6 single bond of meropenem rotates approximately 180 degrees, and this rotation induces localized structural changes in segment A (including residues Tyr308 and Tyr318) of Ldt Mt2 , leading to the formation of several hydrogen bonds (State II), stabilizing the structure of the Ldt Mt2 -meropenem adduct, and resulting in a slow turnover in drug hydrolysis. This mechanism may be shared by carbapenems, such as meropenem and imipenem, which have been reported to inhibit Ldt Mt2 .
Furthermore, we explored the role of tautomerization in stabilizing the complex of Ldt Mt2 and antibiotics. When we performed mass spectrometry assays with cephems such as cepholotin and cefuroxime, a subclass of β-lactams that do not inhibit Ldt Mt2 , we found that cephems also form covalent adducts with Ldt Mt2 (Supplementary information, Table S2 and Figure S6 ). We thus propose that the mechanism of Ldt Mt2 action on cephems is the same as that of Ldt Mt1 action on cephems [14] and involves a tautomerization of the cephem nucleus (a β-lactam ring and a dihydrothiazine ring) (Supplementary information, Figure S5A ). As cephems cannot inhibit Ldt Mt2 , we suggest that tautomerization alone is not sufficient to stabilize the adduct of Ldt Mt2 and cephems. To stabilize the adduct of Ldt Mt2 and carbapenem (or any other potential inhibitor of Ldt Mt2 ), tautomerization is necessary but not sufficient, and the conformational change in the second step likely also plays an important role. The results reported here, together with the reported structure of the BlaC-meropenem complex [15] , reveal the structural basis for the stabilization of enzymecarbapenem adducts and may suggest new strategies for the design of antibiotics derived from β-lactams to fight against XDR M. tuberculosis.
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